FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
UITN trials were performed on UDS in order to standardize and give reference values, as well as provide predictive value of baseline parameters. Most importantly, this work was able to provide evidence for the value of preop UDS. Through this, researchers were able to determine predictors of success and adverse events. The VALUE trial found that in patients desiring surgery for SUI, office evaluation alone for SUI was not inferior to office evaluation plus UDS. There was no difference in severity of incontinence, quality of life, and satisfaction measures between the two groups. In the BE-DRI study, researchers found that the addition of PME to anticholinergic therapy does not improve outcomes in OAB.
Dr. Albo concluded that the UITN has demonstrated that patients are willing to be randomized and surgeons are willing to standardize outcomes and procedures. He also makes note that patient study populations may not be diverse in these trials and because of this, may not be generalizable to the general population.
Presented by: Michael E. Albo, MD
Written by: Cristina Palmer, DO. Female Urology, Pelvic Reconstruction, Voiding Dysfunction Fellow, Department of Urology, UC Irvine Medical Center, Orange, California at the Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction Winter Meeting (SUFU 2018), February 27-March 3, 2018, Austin, Texas